lumicitabine Report issue

Small molecule Experimental
AACT MeSH PubChem

Active Ingredient History

NOW
  • Now
Lumicitabine (ALS-8176) is an antiviral drug which was developed as a treatment for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). It acts as an RNA polymerase inhibitor. While it showed promise in early clinical trials, poor results in Phase IIb trials led to it being discontinued from development for treatment of RSV. Research continues to determine whether it may be useful for the treatment of diseases caused by other RNA viruses, and it has been found to show activity against Nipah virus.   Wikipedia

Chemistry

  • SMILES: CC(C)C(=O)OC[C@@]1(CCl)O[C@@H](n2ccc(N)nc2=O)[C@H](F)[C@@H]1OC(=O)C(C)C
  • InChIKey: MJVKYGMNSQJLIN-KYZVSKTDSA-N
  • Mol. Mass: 433.86
  • ALogP: 1.44
  • ChEMBL Molecule:
    lumicitabine  
More Chemistry

Pharmacology

Alternative names

4'-chloromethyl-2'-deoxy-3',5'-di-o-isobutyryl-2'-fluorocytidine | als-008176 | als-8176 | lumicitabine

Organizations (5)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)


 

Healthy Volunteers (Phase 1)

Metapneumovirus (Phase 2)

Respiratory Syncytial Viruses (Phase 2)

Respiratory Syncytial Virus Infections (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 14
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue